# SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas

> **NCT07635173** · PHASE1 · COMPLETED · sponsor: **Shenzhen Zhenxing Medical Technology Co., Ltd** · enrollment: 35 (actual)

## Conditions studied

- Glioma
- Glioblastomas (GBM)
- High Grade Gliomas

## Interventions

- **DRUG:** SM-1,TMZ

## Key facts

- **NCT ID:** NCT07635173
- **Lead sponsor:** Shenzhen Zhenxing Medical Technology Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-19
- **Primary completion:** 2024-04-22
- **Final completion:** 2026-03-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635173, "SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07635173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*